Travere Therapeutics, Inc.

Travere reported second-quarter 2026 total U.S. net product sales of $161.4 million, including FILSPARI U.S. net product sales of $141.1 million, up approximately 96% year over year, and Thiola/Thiola EC sales of $20.3 million. The company recognized $8.2 million in license and collaboration revenue, bringing total revenue to $169.6 million. Total GAAP R&D and SG&A expenses were $156.4 million, including approximately $22.2 million of noncash stock-based compensation and depreciation expense; royalty expense was approximately $7.1 million. Cash, cash equivalents and marketable securities were approximately $489.2 million as of June 30, 2026. For guidance, management reiterated full-year FILSPARI gross-to-net discounts in the mid-20% range, said third- and fourth-quarter discounts should be slightly higher than Q2, and reaffirmed top-line pegtibatinase data in the second half of 2027.

Eric Dube framed Q2 as an “exceptional” quarter and said Travere has entered a new chapter with momentum across FILSPARI in IgAN, the FSGS launch, pegtibatinase, and civorebrutinib. He emphasized that the company is seeing early FSGS uptake exceed expectations, while IgAN demand also continues to grow despite additional competition. His tone was confident and strategically expansive, repeatedly pointing to durable growth, a scalable infrastructure, and the potential for more than $3 billion in peak annual FILSPARI sales.

Chris Cline highlighted that the quarter delivered exceptional commercial results, with strong sequential and year-over-year growth across the business. He cited FILSPARI growth of approximately 96% year over year to $141.1 million, total U.S. net product sales of $161.4 million, total revenue of $169.6 million, and GAAP operating expenses of $156.4 million. He also said gross-to-net discounts for FILSPARI were slightly lower than Q1, but should be slightly higher in Q3 and Q4 while still landing in the mid-20% range for the full year. On capital structure, he pointed to the $525 million of 0.5% convertible notes due 2032, the repurchase of about $221 million of 2.25% 2029 notes, net proceeds of about $158 million, and the roughly $112.5 million Everest upfront payment after close in July.

Analysts focused heavily on the FSGS launch curve, asking about seasonality, conversion from start forms to paid scripts, the breadth of prescribers, and whether early demand included a bolus. Management said it does not see evidence of a bolus, expects continued demand, and believes FSGS conversion is running ahead of the early IgAN experience, though payer education and formulary work are still ongoing. Questions also probed whether combination therapy with APRIL inhibitors or other branded agents could create payer friction; management said payers understand complementary roles and nephrologists are increasingly thinking in layered treatment approaches. On pipeline and IP, management said pegtibatinase remains on track for H2 2027 top-line data, civorebrutinib will next move toward a U.S. IND, and the company had nothing new to report on FSGS patent prosecution yet.